Background:High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas.This study aimed to evaluate the effect of ifosfamide,cisplatin or carboplatin,and etoposide (ICE)-based regimen as a mobilization regimen on relapsed,refractory,or high-risk aggressive lymphoma.Methods:From June 2001 to May 2013,patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study.The results of the autologous peripheral blood stem cells collection,toxicity,engraftment after ICE-based mobilization regimen were analyzed in this study.Furthermore,risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis.Results:The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients,respectively.The results of stem cell mobilization were excellent.Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 106 CD34+ cells/kg and 68％ had at least 5 × 106 CD34+ cells/kg.Fifty-eight percentage of the patients experienced Grade 4 neutropenia,20％ developed febrile neutropenia,and only 12％ had Grade 4 thrombocytopenia.At a median follow-up of 63.8 months,the 5-year PFS and OS were 64.4％ and 75.3％,respectively.Conclusion:ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.